The FDA has released final postmarket guidance for manufacturers of drug-device combination products.
The guidance outlines how the agency expects manufacturers of combination products and those that make constituent parts of drug-device combinations to report adverse events and product malfunctions.
Get the full story on our sister site, Drug Delivery Business.